Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Cyclooxygenase-2 Inhibition Limits Angiotensin II-Induced DNA Oxidation and Protein Nitration in Humans.

Pialoux V, Poulin MJ, Hemmelgarn BR, Muruve DA, Chirico EN, Faes C, Sola DY, Ahmed SB.

Front Physiol. 2017 Mar 10;8:138. doi: 10.3389/fphys.2017.00138. eCollection 2017.

2.

Demethoxycurcumin Preserves Renovascular Function by Downregulating COX-2 Expression in Hypertension.

Li Y, Tian D, Zhu C, Ren L.

Oxid Med Cell Longev. 2016;2016:9045736. doi: 10.1155/2016/9045736. Epub 2016 Dec 25.

3.

Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study.

Wu LC, Leong PY, Yeo KJ, Li TY, Wang YH, Chiou JY, Wei JC.

Medicine (Baltimore). 2016 Sep;95(36):e4792. doi: 10.1097/MD.0000000000004792.

4.

Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective.

Patrono C.

Br J Clin Pharmacol. 2016 Oct;82(4):957-64. doi: 10.1111/bcp.13048. Epub 2016 Jul 18. Review.

PMID:
27317138
5.

Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population.

Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K.

Int J Med Sci. 2016 Jan 1;13(1):25-38. doi: 10.7150/ijms.13800. eCollection 2016. Review.

6.

Src Tyrosine Kinase Activation by 4-Hydroxynonenal Upregulates p38, ERK/AP-1 Signaling and COX-2 Expression in YPEN-1 Cells.

Jang EJ, Jeong HO, Park D, Kim DH, Choi YJ, Chung KW, Park MH, Yu BP, Chung HY.

PLoS One. 2015 Oct 14;10(10):e0129244. doi: 10.1371/journal.pone.0129244. eCollection 2015.

7.

Vasomotor Reaction to Cyclooxygenase-1-Mediated Prostacyclin Synthesis in Carotid Arteries from Two-Kidney-One-Clip Hypertensive Mice.

Liu B, Li Z, Zhang Y, Luo W, Zhang J, Li H, Zhou Y.

PLoS One. 2015 Aug 26;10(8):e0136738. doi: 10.1371/journal.pone.0136738. eCollection 2015.

8.

Oleocanthal, a phenolic derived from virgin olive oil: a review of the beneficial effects on inflammatory disease.

Parkinson L, Keast R.

Int J Mol Sci. 2014 Jul 11;15(7):12323-34. doi: 10.3390/ijms150712323. Review.

9.

Cyclooxygenase-2 inhibition improves antioxidative defense during experimental hypercholesterolemia.

Ahmed S, Gul S, Gul H, Zia-Ul-Haq M, Ercisli S.

Bosn J Basic Med Sci. 2014 May;14(2):63-9.

10.

Influence of celecoxib on the vasodilating properties of human mesenteric arteries constricted with endothelin-1.

Grześk G, Szadujkis-Szadurska K, Matusiak G, Malinowski B, Gajdus M, Wiciński M, Szadujkis-Szadurski L.

Biomed Rep. 2014 May;2(3):412-418. Epub 2014 Jan 29.

11.

Cyclooxygenase inhibition improves endothelial vasomotor dysfunction of visceral adipose arterioles in human obesity.

Farb MG, Tiwari S, Karki S, Ngo DT, Carmine B, Hess DT, Zuriaga MA, Walsh K, Fetterman JL, Hamburg NM, Vita JA, Apovian CM, Gokce N.

Obesity (Silver Spring). 2014 Feb;22(2):349-55. doi: 10.1002/oby.20505. Epub 2013 Jul 29.

12.

Increased superoxide and endothelial NO synthase uncoupling in blood vessels of Bmal1-knockout mice.

Anea CB, Cheng B, Sharma S, Kumar S, Caldwell RW, Yao L, Ali MI, Merloiu AM, Stepp DW, Black SM, Fulton DJ, Rudic RD.

Circ Res. 2012 Oct 12;111(9):1157-65. doi: 10.1161/CIRCRESAHA.111.261750. Epub 2012 Aug 20.

13.

Test-retest reliability of pulse amplitude tonometry measures of vascular endothelial function: implications for clinical trial design.

McCrea CE, Skulas-Ray AC, Chow M, West SG.

Vasc Med. 2012 Feb;17(1):29-36. doi: 10.1177/1358863X11433188.

14.

Effects of combination therapy with celecoxib and doxycycline on neointimal hyperplasia and inflammatory biomarkers in coronary artery disease patients treated with bare metal stents.

Kim WH, Ko YG, Kang KW, Kim JS, Kim BK, Choi D, Hong MK, Jang Y.

Yonsei Med J. 2012 Jan;53(1):68-75. doi: 10.3349/ymj.2012.53.1.68.

15.

Effects of cyclooxygenase inhibition on cardiovascular function in a hypercholesterolemic swine model of chronic ischemia.

Chu LM, Robich MP, Bianchi C, Feng J, Liu Y, Xu SH, Burgess T, Sellke FW.

Am J Physiol Heart Circ Physiol. 2012 Jan;302(2):H479-88. doi: 10.1152/ajpheart.00146.2011. Epub 2011 Oct 28.

16.

Oxidative stress-dependent cyclooxygenase-2-derived prostaglandin f(2α) impairs endothelial function in renovascular hypertensive rats.

Tian XY, Wong WT, Leung FP, Zhang Y, Wang YX, Lee HK, Ng CF, Chen ZY, Yao X, Au CL, Lau CW, Vanhoutte PM, Cooke JP, Huang Y.

Antioxid Redox Signal. 2012 Feb 15;16(4):363-73. doi: 10.1089/ars.2010.3874. Epub 2011 Dec 2.

17.

C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.

Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM.

Cancer Prev Res (Phila). 2011 Aug;4(8):1172-80. doi: 10.1158/1940-6207.CAPR-10-0403.

18.

Hypercholesterolemia and chronic ischemia alter myocardial responses to selective cyclooxygenase-2 inhibition.

Chu LM, Robich MP, Lassaletta A, Burgess T, Liu Y, Sellke N, Sellke FW.

J Thorac Cardiovasc Surg. 2011 Sep;142(3):675-81. doi: 10.1016/j.jtcvs.2011.06.005. Epub 2011 Jul 16.

19.

Endothelium-mediated control of vascular tone: COX-1 and COX-2 products.

Félétou M, Huang Y, Vanhoutte PM.

Br J Pharmacol. 2011 Oct;164(3):894-912. doi: 10.1111/j.1476-5381.2011.01276.x. Review.

20.

Loxoprofen Sodium, a Non-Selective NSAID, Reduces Atherosclerosis in Mice by Reducing Inflammation.

Hamaguchi M, Seno T, Yamamoto A, Kohno M, Kadoya M, Ishino H, Ashihara E, Kimura S, Tsubakimoto Y, Takata H, Yoshikawa T, Maekawa T, Kawahito Y.

J Clin Biochem Nutr. 2010 Sep;47(2):138-47. doi: 10.3164/jcbn.10-33. Epub 2010 Jul 3.

Supplemental Content

Support Center